Meeting report: Consensus from the first and second Global Workshops in Melanoma November 19-20, 2008

Pigment Cell and Melanoma Research

Volumn 22, Issue 5, 2009, Pages 532-543

  Agarwala, Sanjiv S ^a,b   Becker, Jurgen C ^c   Eggermont, Alexander M ^d   Flaherty, Keith T ^e   Garbe, Claus ^f   Goldstein, Alisa M ^g   Halpern, Allan ^h   Kashani Sabet, Mohammed ⁱ   Hauschild, Axel ^j   Kirkwood, John M ^k,l   Leachman, Sancy ^m   Lorigan, Paul ⁿ   McMahon, Martin ⁱ   Messina, Jane ^o   Ribas, Antoni ^p   Samlowski, Wolfram E ^q   Schadendorf, Dirk ^r   Sondak, Vernon K ^o,s  

^a St Luke's Cancer Center   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g NATIONAL CANCER INSTITUTE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF KIEL   (Germany)

^k UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^m UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

ⁿ CHRISTIE HOSPITAL   (United Kingdom)

^o H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q NEVADA CANCER INSTITUTE   (United States)

^r UNIVERSITY OF DUISBURG ESSEN   (Germany)

^s UNIVERSITY OF SOUTH FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; BEVACIZUMAB; BIOLOGICAL MARKER; CANVAXIN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; LOMEGUATRIB; PACLITAXEL; PEGINTERFERON ALPHA2B; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P16; RAF PROTEIN; SORAFENIB; STAT1 PROTEIN; STAT3 PROTEIN; SUNITINIB; SUNSCREEN; TEMOZOLOMIDE; TICILIMUMAB; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ADVANCED CANCER; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CONSENSUS; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; EDEMA; GENE MUTATION; HUMAN; LOW DRUG DOSE; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTECTIVE CLOTHING; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; CONSENSUS; FEMALE; HUMANS; IMMUNE SYSTEM; MALE; MELANOMA; SIGNAL TRANSDUCTION;

EID: 69449090997     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2009.00602.x     Document Type: Conference Paper

References (8)

1. Bedikian, A.Y., Millward, M., Pehamberger, H. et al. (2006). Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24, 4738 4745.
2. Eggermont, A.M., Suciu, S., Mackie, R. et al. (2005). Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366, 1189 1196.
3. Eggermont, A.M., Suciu, S., Santinami, M. et al. (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372, 117 126.
4. Gogas, H., Ioannovich, J., Dafni, U. et al. (2006). Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709 718.
5. Hauschild, A., Agarwala, S.S., Trefzer, U. et al. (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823 2830.
6. Hodi, F.S., Friedlander, P., Corless, C.L. et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 2046 2051.
7. Korn, E.L., Liu, P.Y., Lee, S.J. et al. (2008). Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26, 527 534.
8. Ribas, A., Hauschild, A., Kefford, R. Al., E. (2008). Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol. 26 (suppl 1011s (abstract (LBA9011).